This device has an outer fabric skirt that has been shown to reduce dramatically the incidence of paravalvular aortic insufficiency, a major problem in the application of previous TAVR devices to bicuspid aortic stenosis. This study strongly suggests that this new device is effective in preventing paravalvular aortic insufficiency after TAVR in bicuspid arctic stenosis, as it has been in tricuspid senile aortic stenosis.
The reported outcomes from this study do raise 3 important concerns that will require special attention as we consider the extension of TAVR in bicuspid aortic stenosis to lower risk patients: higher mortality, increased new pacemaker requirement, and a high rate of asymmetrical stent deployment. has reported that he has no relationships relevant to the contents of this paper to disclose. As we consider extension of TAVR to lower risk patients, these 3 concerns-a higher mortality rate, a pacemaker rate of 10% to 25%, and incomplete stent expansion in 38% of patients-become magnified in importance. In patients with 5-or even 10-year life expectancy, permanent pacemakers may not be a huge concern. However, in a patient with life expectancy more than 15 to 20 years, the need for a permanent pacemaker becomes a major liability with regard to both quality and length of life.
Similarly, a decrease in valve durability from 15 to 20 years down to 7 to 10 years becomes a major concern in those patients with longer life expectancy. This is especially true in patients receiving 
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